U.S. Peripheral Nerve Injuries Market Share to Witness Significant Revenue Growth

Comments · 60 Views

The U.S. peripheral nerve injuries market size was valued at USD 465.0 million in 2024 and is projected to grow at a CAGR of 7.4% from 2025 to 2030.

U.S. Peripheral Nerve Injuries Industry

The U.S. peripheral nerve injuries market size was valued at USD 465.0 million in 2024 and is projected to grow at a CAGR of 7.4% from 2025 to 2030. This industry growth can be attributed to technological advancements in surgical techniques, increasing demand for minimally invasive procedures, and the rising proportion of the geriatric population that is more susceptible to these injuries.

According to a research study published by Merck & Co., Inc., aging can slow the speed of peripheral nervous system (PNS) regeneration, which makes older people more vulnerable to injuries and diseases. According to an article published by the PRB, in January 2024, the number of people aged 65 and older in the U.S. is expected to increase to 82 million by 2050 from around 58 million in 2022. This rising proportion of the geriatric population and their susceptibility to injuries is likely to add to the market growth over the forecast period.

In addition, the growing inclination toward driving and increasing incidents of related accidents leading to peripheral nerve injuries are likely to drive the market demand over the forecast period. For instance, as per the research article published by the National Library of Medicine in August 2023, motor vehicle crashes accounted for 46% of peripheral nerve injuries, and motor vehicle crashes accounted for 9.9%. In addition, the increasing number of traumatic injuries due to increasing sports activities, workplace accidents, and other daily activities is also expected to cause peripheral nerve damage and drive market growth.

The increasing research and development and increasing emphasis on technological advancements are further expected to drive market growth. For instance, there have been growing research efforts in peripheral nerve regeneration that focus on accelerating peripheral nerve development through the use of pluripotent stem cells, exosome technology, pharmacological interventions, and the bioengineering of nerve conduits. 

Gather more insights about the market drivers, restrains and growth of the U.S. Peripheral Nerve Injuries market

U.S. Peripheral Nerve Injuries Market Segments Highlights:

  • Based on product/therapies, Nerve grafting segment dominated the U.S. peripheral nerve injury market share in 2024, accounting for 65.1%, owing to rapid advancements in nerve grafting techniques, such as autografts, allografts, and synthetic conduits
  • Based on surgery, direct nerve repair segment dominated the U.S. peripheral nerve injury market and held the largest revenue share of nearly 42.5%. It is considered the gold standard of surgical treatment for severe cases
  • Based on application, upper extremities segment held the largest U.S. peripheral nerve injury market share in 2024, accounting for 81.2%. increasing incidence of accidental falls and medical conditions, such as Guillain-Barre syndrome, diabetes, & carpal tunnel syndrome, is expected to drive the segment
  • Based on end use, hospitals segment dominated the market in 2024. Increasing number of hospitals and surgical cases in hospitals are expected to boost the segment.

U.S. Peripheral Nerve Injuries Market Report Segmentation

Grand View Research has segmented the U.S. peripheral nerve injury market based on products/therapies, surgery, application, and end-use:

U.S. Peripheral Nerve Injuries Products/Therapies Outlook (Revenue, USD Million, 2018 - 2030)

  • Nerve Grafting
    • Autograft
    • Allograft
    • Stem Cell Therapy
  • Biomaterial
    • Nerve Conduit
    • Nerve Protector
    • Nerve Connector
    • Nerve Wraps

U.S. Peripheral Nerve Injuries Surgery Outlook (Revenue, USD Million, 2018 - 2030)

  • Direct Nerve Repair
  • Nerve Grafting
  • Stem Cell Therapy
  • Carpal Tunnel Release
  • Internal Neurolysis
  • Neurorrhaphy

U.S. Peripheral Nerve Injuries Surgery Outlook (Revenue, USD Million, 2018 - 2030)

  • Upper Extremities
  • Lower Extremities

U.S. Peripheral Nerve Injuries Surgery Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others

Key U.S. Peripheral Nerve Injuries Company Insights

Some of the key companies operating in the U.S. peripheral nerve injury market include Axogen Corporation., Stryker, Regenity, and Integra LifeSciences Corporation. These companies engaged in various strategies to increase their market share. This includes techniques such as developing new and innovative products, mergers and acquisitions, and expansion activities.

  • Axogen Corporation is a medical technology company that develops and commercializes surgical nerve repair and regeneration solutions. It addresses peripheral nerve injuries, including those resulting from trauma, tumor resections, and other surgical procedures. The company offers a range of products designed to support nerve regeneration, such as Avance Nerve Graft, a human nerve allograft that can help regenerate damaged nerves.
  • Stryker is a global company that develops a wide range of products and services in orthopedic, surgical, neurotechnology, and spine specialties. The company's peripheral nerve portfolio consists of type I collagen conduits and wrap.

Key U.S. Peripheral Nerve Injuries Company Insights

  • Axogen Corporation.
  • Stryker
  • Regenity
  • Integra LifeSciences Corporation.
  • TOYOBO CO., LTD.
  • Alafair Biosciences, Inc.
  • SYNOVIS MICRO COMPANIES ALLIANCE, INC., (BAXTER INTERNATIONAL INC.)

Recent Developments

  • In October 2024, the U.S. FDA granted the Breakthrough Device Designation to the NTX-001 developed by Neuraptive Therapeutics, Inc., to treat peripheral nerve injury that requires repair.
  • In October 2024, Orthocell Ltd., a company specializing in regenerative medicine, secured around USD 11.28 million to introduce its nerve repair product, Remplir, into the U.S. market.
  • In September 2024, Axogen announced the completion of its submission process for Biologics License Application (BLA) for Avance Nerve Graft to the U.S. FDA.

Order a free sample PDF of the U.S. Peripheral Nerve Injuries Market Intelligence Study, published by Grand View Research.

Comments